Skip to main content
. 2016 Apr 6;11(4):e0152384. doi: 10.1371/journal.pone.0152384

Fig 6. Induction of CD8+ T cell lines that are reactive to cancer antigens by CD14-ML-DC obtained from HNC patients.

Fig 6

Peripheral blood CD8+ T cells obtained from HLA-A*24:02-positive HNC patients were co-cultured with autologous CD14-ML-DC pre-loaded with a peptide mixture (CDCA156-64, KIF20A66-75, LY6K177-186 and IMP-3508–516) to induce T cell lines that were reactive to the peptides under a schedule similar to that shown in Fig 4A. On days 7 and 14, the CD8+ T cells were re-stimulated with peptide-loaded CD14-ML-DC. (A, C) On day 21, the number of CD8+ T cells responding to the peptides were analyzed by an IFN-γ ELISPOT assay. An HIV-peptide was used as a control peptide. (B, D) On day 21, the T cells were recovered and stained with an anti-CD8 mAb and a HLA-A*24:02/CDCA156-64, HLA-A*24:02/KIF20A66-75 or HLA-A*24:02/LY6K177-186 tetramer. The numbers in the figure indicate the percentage of the CD8+ T cells that were positively stained with the tetramer from the HLA-peptide complex. The results for the cancer patient 1 (A, B) and the cancer patient 2 (C, D) are shown.